Anti-a-enolase antibodies in systemic sclerosis identify a subset of patients with diffuse cutaneous sclerosis and interstitial lung disease Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008
Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003
Clinical manifestations of systemic sclerosis (SS) accompanied with pulmonary involvement Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013
Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020
Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis Source: Eur Respir J 2011; 38: 1355-1360 Year: 2011
Systemic sclerosis patients‘ sera recognize collagen V in experimental scleroderma lung fibrosis Source: Annual Congress 2011 - The ageing pulmonary interstitium Year: 2011
Clinical characteristics of interstitial lung fibrosis in progressive systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 95s Year: 2006
The natural course of systemic sclerosis patients with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005
Proteomic analysis of BALf in systemic sclerosis patients (SSp) with or without pulmonary fibrosis (ILD) Source: Eur Respir J 2005; 26: Suppl. 49, 202s Year: 2005
Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease Source: Eur Respir Rev, 27 (148) 170102; 10.1183/16000617.0102-2017 Year: 2018
Systemic autoimmunity and pulmonary fibrosis Source: International Congress 2017 – GR3 Scientific Grand Round: Autoimmunity in chronic lung disease Year: 2017
Pulmonary hypertension in systemic sclerosis: different phenotypes Source: Eur Respir Rev, 26 (145) 170056; 10.1183/16000617.0056-2017 Year: 2017
Pulmonary function in progressive systemic sclerosis Source: Eur Respir J 2002; 20: Suppl. 38, 62s Year: 2002
Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy Source: Eur Respir J 2009; 33: 371-379 Year: 2009
Membrane diffusion and capillary blood volume in systemic sclerosis-associated pulmonary arterial hypertension (SScPAH) and systemic sclerosis (SSc) without PAH Source: Eur Respir J 2007; 30: Suppl. 51, 342s Year: 2007
Pulmonary involvement in systemic sclerosis Source: Eur Respir Monogr 2019; 86: 90-105 Year: 2019
Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020
Pulmonary functions in systemic sclerosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012
Lung function and pulmonary hypertension in systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 548s Year: 2006
Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus Source: Eur Respir Rev 2011; 20: 277-286 Year: 2011